C18:1 Ceramide (d18:1/18:1(9Z))
| Code | Size | Price |
|---|
| TAR-T35808-5mg | 5mg | £167.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
C18:1 Ceramide is a naturally occurring ceramide.[1][2][3] Levels of C18:1 ceramide are elevated in overweight and insulin-resistant mice and cattle.[1][2] C18:1 Ceramide is also increased in the plasma and ovarian tissue of patients with advanced ovarian cancer. [3]
CAS:
5966-28-9
Formula:
C36H69NO3
Molecular Weight:
563.952
Purity:
0.98
SMILES:
CCCCCCCCCCCCCC=C[C@@H](O)[C@H](CO)NC(=O)CCCCCCCC=C/CCCCCCCC
References
Knapp, P., Bodnar, L., B?achnio-Zabielska, A., et al. Plasma and ovarian tissue sphingolipids profiling in patients with advanced ovarian cancer. Gynecol. Oncol. 147(1), 139-144 (2017).
Sajan, M.P., Ivey, R.A., Lee, M.C., et al. Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation. J. Lipid Res. 56(1), 70-80 (2015).
Rico, J.E., Bandaru, V.V., Dorskind, J.M., et al. Plasma ceramides are elevated in overweight Holstein dairy cows experiencing greater lipolysis and insulin resistance during the transition from late pregnancy to early lactation. J. Dairy Sci. 98(11), 7757-7770 (2015).